Zacks: Brokerages Anticipate BioCardia, Inc. (NYSE:BCDA) Will Post Quarterly Sales of $30,000.00

Share on StockTwits

Brokerages expect BioCardia, Inc. (NYSE:BCDA) to announce sales of $30,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for BioCardia’s earnings. BioCardia reported sales of $190,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 84.2%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 17th.

On average, analysts expect that BioCardia will report full year sales of $130,000.00 for the current fiscal year, with estimates ranging from $120,000.00 to $130,000.00. For the next financial year, analysts expect that the business will report sales of $370,000.00, with estimates ranging from $120,000.00 to $630,000.00. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover BioCardia.

BioCardia (NYSE:BCDA) last announced its earnings results on Thursday, August 13th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.21). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.18 million.

Shares of NYSE BCDA traded down $0.07 on Tuesday, reaching $2.30. 19,080 shares of the company traded hands, compared to its average volume of 101,542. BioCardia has a fifty-two week low of $2.01 and a fifty-two week high of $6.75. The company has a 50 day moving average of $2.32 and a 200 day moving average of $2.97.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

Further Reading: Trading Strategy Examples and Plans

Get a free copy of the Zacks research report on BioCardia (BCDA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with's FREE daily email newsletter.